Skip to content
October 25–27, 2027 · Orlando

Talk Details · Diabetes 2025

Comparative outcomes of antihypertensive therapy in black vs non hispanic white patients with hypertension and cardiovascular disease

Oral · In-Person · Day 1

Abstract

About this talk

This retrospective, multicenter cohort study evaluated the comparative effectiveness of calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), and thiazide diuretics in reducing cardiovascular events among hypertensive African American and non-Hispanic White populations. Using data from HCA Healthcare’s multicenter database (2016–2022), we analyzed over 6,000 adult patients with documented hypertension and cardiovascular comorbidities. Patients were stratified by race and first-line antihypertensive class. The primary endpoint was a composite of myocardial infarction, stroke, hospitalization for heart failure, or cardiovascular death. Among African American patients, CCBs and thiazide diuretics were more effective at reducing cardiovascular events compared to ACEI/ARBs. In contrast, ACEI/ARBs showed comparable effectiveness across both racial groups when combined with diuretics. This study supports current hypertension management guidelines emphasizing race-specific therapy and reinforces the need for individualized antihypertensive strategies to mitigate long-term cardiovascular risk.

Speaker

About the speaker

Anil Harrison

Anil Harrison

Midwestern University, United States

View full speaker profile →

Join the Diabetes 2027 delegation

Orlando · October 25–27, 2027· Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.